An updated patent review on PD-1/PD-L1 antagonists (2022-present)
{{output}}
Introduction: PD-L1, via its interactions with PD-1, constitutes a key immune checkpoint that allows cancer cells to escape immune surveillance. Targeting PD-1/PD-L1 with monoclonal antibodies (mAbs) led to spectacular success in... ...
